| Accession |
PRJCA012595 |
| Title |
Phase III trial of pyrrotinib maleate tablets plus trastuzumab plus docetaxel versus placebo plus trastuzumab plus docetaxel in HER2-positive recurrent/metastatic breast cancer |
| Relevance |
Medical |
| Data types |
clinical,image,Metabolic,Biomarker,Genetic data
|
| Organisms |
Homo sapiens
|
| Description |
To evaluate progression-free survival (PFS) in patients with HER2-positive recurrent/metastatic breast cancer treated with pyrrotinib maleate tablets plus trastuzumab plus docetaxel versus placebo plus trastuzumab plus docetaxel as first-line therapy. |
| Sample scope |
Multiisolate |
| Release date |
2022-10-19 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| NA
|
|
NA
|
|
|
|
| Submitter |
wanqiu
liang (wanqiu.liang@hengrui.com)
|
| Organization |
Jiangsu Hengrui Pharmaceutical Co. LTD |
| Submission date |
2022-10-19 |
